Literature DB >> 29734512

Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor.

A de Jong1, R J Dirven1, J A Oud1, D Tio1, B J M van Vlijmen1, J Eikenboom1.   

Abstract

Essentials Substitution therapy for von Willebrand (VW) disease leaves mutant VW factor (VWF) unhindered. Presence of mutant VWF may negatively affect phenotypes despite treatment. Inhibition of VWF by allele-specific siRNAs targeting single-nucleotide polymorphisms is effective. Allele-specific inhibition of VWF p.Cys2773Ser improves multimerization.
SUMMARY: Background Treatment of the bleeding disorder von Willebrand disease (VWD) focuses on increasing von Willebrand factor (VWF) levels by administration of desmopressin or VWF-containing concentrates. Both therapies leave the production of mutant VWF unhindered, which may have additional consequences, such as thrombocytopenia in patients with VWD type 2B, competition between mutant and normal VWF for platelet receptors, and the potential development of intestinal angiodysplasia. Most cases of VWD are caused by dominant-negative mutations in VWF, and we hypothesize that diminishing expression of mutant VWF positively affects VWD phenotypes. Objectives To investigate allele-specific inhibition of VWF by applying small interfering RNAs (siRNAs) targeting common single-nucleotide polymorphisms (SNPs) in VWF. This approach allows allele-specific knockdown irrespective of the mutations causing VWD. Methods Four SNPs with a high predicted heterozygosity within VWF were selected, and siRNAs were designed against both alleles of the four SNPs. siRNA efficiency, allele specificity and siRNA-mediated phenotypic improvements were determined in VWF-expressing HEK293 cells. Results Twelve siRNAs were able to efficiently inhibit single VWF alleles in HEK293 cells that stably produce VWF. Transient cotransfections of these siRNAs with two VWF alleles resulted in a clear preference for the targeted allele over the untargeted allele for 11 siRNAs. We also demonstrated siRNA-mediated phenotypic improvement of the VWF multimerization pattern of the VWD type 2A mutation VWF p.Cys2773Ser. Conclusions Allele-specific siRNAs are able to distinguish VWF alleles on the basis of one nucleotide variation, and are able to improve a severe multimerization defect caused by VWF p.Cys2773Ser. This holds promise for the therapeutic application of allele-specific siRNAs in dominant-negative VWD.
© 2018 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  single-nucleotide polymorphism; small interfering RNA; therapeutics; von Willebrand disease; von Willebrand factor

Mesh:

Substances:

Year:  2018        PMID: 29734512     DOI: 10.1111/jth.14140

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  9 in total

1.  Identification of von Willebrand factor D4 domain mutations in patients of Afro-Caribbean descent: In vitro characterization.

Authors:  Marie-Daniéla Dubois; Ivan Peyron; Olivier-Nicolas Pierre-Louis; Serge Pierre-Louis; Johalène Rabout; Pierre Boisseau; Annika de Jong; Sophie Susen; Jenny Goudemand; Rémi Neviere; Pascal Fuseau; Olivier D Christophe; Peter J Lenting; Cécile V Denis; Caterina Casari
Journal:  Res Pract Thromb Haemost       Date:  2022-06-15

2.  Lowering the increased intracellular pH of human-induced pluripotent stem cell-derived endothelial cells induces formation of mature Weibel-Palade bodies.

Authors:  Gesa L Tiemeier; Rozemarijn de Koning; Gangqi Wang; Sarantos Kostidis; Rosalie G J Rietjens; Wendy M P J Sol; Sébastien J Dumas; Martin Giera; Cathelijne W van den Berg; Jeroen C J Eikenboom; Bernard M van den Berg; Peter Carmeliet; Ton J Rabelink
Journal:  Stem Cells Transl Med       Date:  2020-03-12       Impact factor: 6.940

3.  Variability of von Willebrand factor-related parameters in endothelial colony forming cells.

Authors:  Annika de Jong; Ester Weijers; Richard Dirven; Suzan de Boer; Jasmin Streur; Jeroen Eikenboom
Journal:  J Thromb Haemost       Date:  2019-07-22       Impact factor: 5.824

4.  ADAMTS-13 and bleeding phenotype in von Willebrand disease.

Authors:  Johan Boender; Angelique Nederlof; Karina Meijer; Evelien P Mauser-Bunschoten; Marjon H Cnossen; Karin Fijnvandraat; Johanna G van der Bom; Joke de Meris; Britta A P Laros-van Gorkom; Karin P M van Galen; Jeroen Eikenboom; Moniek P M de Maat; Frank W G Leebeek
Journal:  Res Pract Thromb Haemost       Date:  2020-10-31

5.  von Willebrand Factor: A Central Regulator of Arteriovenous Fistula Maturation Through Smooth Muscle Cell Proliferation and Outward Remodeling.

Authors:  Suzanne L Laboyrie; Margreet R de Vries; Alwin de Jong; Hetty C de Boer; Reshma A Lalai; Laisel Martinez; Roberto I Vazquez-Padron; Joris I Rotmans
Journal:  J Am Heart Assoc       Date:  2022-08-05       Impact factor: 6.106

Review 6.  Von Willebrand Disease: From In Vivo to In Vitro Disease Models.

Authors:  Suzan de Boer; Jeroen Eikenboom
Journal:  Hemasphere       Date:  2019-09-27

7.  Ex vivo Improvement of a von Willebrand Disease Type 2A Phenotype Using an Allele-Specific Small-Interfering RNA.

Authors:  Annika de Jong; Richard J Dirven; Johan Boender; Ferdows Atiq; Seyed Yahya Anvar; Frank W G Leebeek; Bart J M van Vlijmen; Jeroen Eikenboom
Journal:  Thromb Haemost       Date:  2020-08-15       Impact factor: 5.249

8.  Endothelial characteristics in healthy endothelial colony forming cells; generating a robust and valid ex vivo model for vascular disease.

Authors:  Suzan de Boer; Mackenzie Bowman; Colleen Notley; Aomei Mo; Patricia Lima; Annika de Jong; Richard Dirven; Ester Weijers; David Lillicrap; Paula James; Jeroen Eikenboom
Journal:  J Thromb Haemost       Date:  2020-08-18       Impact factor: 5.824

9.  Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease.

Authors:  Johan Boender; Ferdows Atiq; Marjon H Cnossen; Johanna G van der Bom; Karin Fijnvandraat; Joke de Meris; Moniek P M de Maat; Karin P M van Galen; Britta A P Laros-van Gorkom; Karina Meijer; Jeroen Eikenboom; Frank W G Leebeek
Journal:  Hemasphere       Date:  2021-02-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.